KEAP1

Overview

KEAP1 (Kelch-like ECH-associated protein 1) is a cytoplasmic regulatory protein best known for controlling the stability of nuclear factor erythroid 2-related factor 2 (NRF2), a central transcription factor in cellular antioxidant defense. Under basal conditions, KEAP1 functions as part of a Cullin3-based ubiquitin ligase complex that promotes NRF2 degradation, thereby limiting activation of antioxidant and cytoprotective genes. When KEAP1-mediated repression is reduced, NRF2 can accumulate, translocate to the nucleus, and induce downstream protective programs such as heme oxygenase 1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1).

Biomedically, KEAP1 is important because it sits at the center of the KEAP1-NRF2 axis, a pathway implicated in oxidative stress responses, ischemic injury, diabetic nephropathy, septic acute kidney injury, Parkinson’s disease-related biology, and broader context-dependent stress adaptation. Recent work also highlights that KEAP1 pathway behavior is not determined solely by mutation status; rather, pathway output can vary with cellular context, protein interactions, and post-translational regulation.

Role in Recent Research

Recent studies have examined KEAP1 as a mechanistic node in oxidative stress biology and as a target for pathway modulation. In one study, phosphorylation of Cullin3 by the pseudokinase ALDH18A1 was reported to disrupt KEAP1-mediated NRF2 degradation. The authors described that this phosphorylation inhibits Cullin3 neddylation and weakens its interaction with KEAP1, impairing the ubiquitin ligase activity of the Cullin3-KEAP1 complex and leading to NRF2 stabilization. This work reinforces the idea that KEAP1-dependent NRF2 turnover can be altered indirectly through regulation of the Cullin3 scaffold.

Several pharmacology-oriented studies used KEAP1 as a pathway target in disease models characterized by oxidative stress. In ischemic stroke research, poliumoside was reported to alleviate oxidative stress and improve mitochondrial function in an oxygen-glucose deprivation/reperfusion context. Mechanistically, the compound activated the KEAP1/NRF2 antioxidant pathway, promoted NRF2 nuclear translocation, and increased downstream antioxidant proteins HO-1 and NQO1. This places KEAP1 within a protective signaling axis relevant to neuronal injury and reactive oxygen species handling.

In diabetic nephropathy, cafestol was reported to exert renoprotective effects through activation of the KEAP1-NRF2 axis independent of glycemic control. The study found reduced renal Keap1 mRNA expression together with increased cytoplasmic and nuclear NRF2 protein levels, indicating pathway activation without changes in NRF2 transcript abundance. This suggests that KEAP1 suppression can be associated with enhanced antioxidant signaling in kidney disease, including in the setting of α-streptozocin-induced diabetic injury models.

Another kidney-focused study on septic acute kidney injury reported increased expressions of KEAP1 and p62 in the context of nicotiflorin treatment, alongside mitochondrial restoration and oxidative stress reduction. Although the sentence provided does not specify a direct mechanistic conclusion for KEAP1, it indicates that KEAP1 was measured as part of the oxidative stress response network in renal injury research, likely in relation to NRF2-linked signaling and inflammatory stress markers such as interleukin-6 and other proinflammatory cytokines.

KEAP1 has also been used as a target in computational peptide design. High-PepBinder, a protein language model-guided latent diffusion framework, was applied to representative targets including KEAP1, XIAP, and EGFR. The generated peptides were reported to preserve key binding geometries and interface patterns of reference peptides in predicted complexes while maintaining sequence diversity and favorable predicted properties. This suggests that KEAP1 is being explored not only as a biological regulator but also as a structurally tractable target for affinity-aware peptide discovery.

A broader translational analysis of the NRF2 readout emphasized that the KEAP1-NRF2 axis is frequently altered in disease, but that mutation status alone does not fully capture biological heterogeneity or context dependence. This is relevant to KEAP1 because it underscores the need to interpret KEAP1-associated pathway activity using functional readouts rather than genomic alteration alone.

Key Publications

Jun Phosphorylation of Cullin3 by the pseudokinase ALDH18A1 disrupts KEAP1-mediated NRF2 degradation. (Biochemical and biophysical research communications, 2026, PMID 41996736): "This phosphorylation inhibits Cullin3 neddylation and disrupts its interaction with KEAP1, thereby impairing the ubiquitin ligase activity of the Cullin3-KEAP1 complex and leading to NRF2 stabilization."
Jun Poliumoside alleviates oxidative stress and improves mitochondrial function to alleviate ischemic stroke injury. (European journal of pharmacology, 2026, PMID 42134761): "Mechanistically, POL activated the Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) pathway antioxidant pathway, promoting Nrf2 nuclear translocation and upregulating downstream proteins Heme oxygenase 1 (HO-1) and NAD(P)H quinone dehydrogenase 1 (NQO1)."
May Cafestol ameliorates diabetic nephropathy via Keap1-Nrf2 axis activation: A novel renoprotective mechanism independent of glycemic control. (PloS one, 2026, PMID 42133719): "Cafestol treatment also reduced renal Keap1 mRNA expression and increased cytoplasmic and nuclear Nrf2 protein levels, indicating that Cafestol activates the Nrf2 pathway without altering Nrf2 mRNA expression."
Apr High-PepBinder: A pLM-Guided Latent Diffusion Framework for Affinity-Aware Target-Specific Peptide Design. (Journal of chemical information and modeling, 2026, PMID 41934387): "For representative targets, including KEAP1, XIAP and EGFR, the generated peptides preserve key binding geometries and interface patterns of reference peptides in predicted complexes, while maintaining sequence diversity and favorable predicted properties."
Apr The NRF2 readout beyond genotyping†. (The Journal of pathology, 2026, PMID 41944556): "Until now, clinical and translational efforts have largely focused on recurrent genomic alterations in the Kelch-like ECH-associated protein 1-nuclear factor erythroid 2-related factor 2 (NRF2) axis, yet mutation status alone often fails to capture the biological heterogeneity and context dependence of NRF2 pathway dysregulation."
Apr Efficacy of nicotiflorin in ameliorating septic acute kidney injury: the role of PINK1/parkin in mitochondrial restoration and oxidative stress reduction. (Renal failure, 2026, PMID 41730753): "...increased expressions of kelch-like ECH-associated protein 1 (KEAP1) and p62."